Peptides Academy
CagriSema
Novo Nordisk
CagriSema is a once-weekly subcutaneous injection that combines cagrilintide, a long-acting amylin analogue, with semaglutide, a GLP-1 receptor agonist that is already approved on its own. Amylin and GLP-1 reduce food intake through partly different pathways, so the combination is meant to give more weight loss than either drug alone. Evidence: in the phase 3a REDEFINE 1 trial (3,417 adults with overweight or obesity, no diabetes, 68 weeks), mean weight change was -20.4% with CagriSema versus -3.0% with placebo. In REDEFINE 2 (1,206 adults with obesity and type 2 diabetes), it was -13.7% versus -3.4%, and 73.5% reached an HbA1c of 6.5% or less. In REDEFINE 5 in Japan and Taiwan, CagriSema beat semaglutide 2.4 mg alone (-18.4% versus -11.9%). Gastrointestinal adverse events affected about 73–80% of participants on CagriSema in REDEFINE 1 and 2, mostly transient and mild to moderate. Regulatory status: as of this update there is no FDA approval (no Drugs@FDA record). CagriSema is investigational and is only available in clinical trials; products sold online under this name are not the investigational medicine. Approved options such as semaglutide and tirzepatide remain the standard of care.
Specifications
| Origin / Manufacturer | Fixed-dose combination of two synthetic peptides |
| Active Components | Cagrilintide (amylin analog)Semaglutide (GLP-1 receptor agonist) |
| Storage | Not established in public labeling (investigational) |
| Shelf Life | Not established (investigational) |
| Form Factor | Subcutaneous injection, once weekly (fixed-dose combination) |
Clinical Evidence
Clinical report reference
Clinical report reference
Clinical report reference
Clinical report reference
Clinical report reference
Clinical report reference
Frequently Asked Questions
Sources & References
Every clinical claim on this page traces to a primary peer-reviewed source.
- 1Enebo LB, Berthelsen KK, Kankam M, et al.. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397(10286):1736-1748. doi:10.1016/S0140-6736(21)00845-X PMID:33894838
- 2Frias JP, Deenadayalan S, Erichsen L, et al.. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023;402(10403):720-730. doi:10.1016/S0140-6736(23)01163-7 PMID:37364590
- 3Garvey WT, Blüher M, Osorto Contreras CK, et al.. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2025;393(7):635-647. doi:10.1056/NEJMoa2502081 PMID:40544433
- 4Davies MJ, Bajaj HS, Broholm C, et al.. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. New England Journal of Medicine. 2025;393(7):648-659. doi:10.1056/NEJMoa2502082 PMID:40544432
- 5Yamauchi T, Becker NP, Hagemann CA, et al.. Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial. Lancet Diabetes & Endocrinology. 2026;14(6):450-462. doi:10.1016/S2213-8587(25)00402-4 PMID:42009015
Reviewed by
Peptides Academy Editorial
Editorial Team
All clinical claims cross-checked against primary sources. Read our editorial policy →
Related Peptides
Amycretin
Novo Nordisk
An investigational single-molecule GLP-1 and amylin receptor agonist from Novo Nordisk, now named zenagamtide, studied as a once-weekly injection and a once-daily tablet for obesity and type 2 diabetes. It is not approved anywhere.
Cagrilintide
Novo Nordisk
An investigational long-acting amylin analogue from Novo Nordisk, studied alone and with semaglutide (CagriSema). In the phase 3 REDEFINE 1 trial, CagriSema produced a mean 20.4% weight loss at 68 weeks (vs 3.0% on placebo). Not FDA-approved.
Petrelintide
Zealand Pharma
An investigational long-acting human amylin analog from Zealand Pharma, given as a once-weekly injection for obesity. In the 42-week ZUPREME 1 phase 2 trial it produced about 8–10% mean weight loss at 28 weeks, with nausea as the main side effect. Not approved anywhere.
Semaglutide
Ozempic / Wegovy / Rybelsus
Long-acting GLP-1 receptor agonist — FDA-approved for type-2 diabetes and chronic weight management, landmark for its ~15% mean weight reduction in STEP trials.
Tirzepatide
Mounjaro / Zepbound
First-in-class dual GIP/GLP-1 receptor agonist — SURMOUNT trials showed ~20% mean weight reduction and superior A1c control versus semaglutide.